Hemato-oncology / Original Article
Reduced-intensity chemotherapy with tyrosine kinase inhibitor followed by allogeneic transplantation is effective in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Jung Min Lee, Do Young Kim, Hee Jeong Cho, Joon Ho Moon, Sang Kyun Sohn, Ho Jin Shin, Young Rok Do, Mi Hwa Heo, Min Kyoung Kim, Young Seob Park, Dong Won Baek
Korean J Intern Med. 2025;40(1):124-134. Published online January 1, 2025
Background/Aims: To determine the effectiveness of tyrosine kinase inhibitor (TKI) plus reduced-intensity therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL), this retrospective study compared treatment outcomes and induction..
|
|
Hemato-oncology / Erratum
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Korean J Intern Med. 2023;38(4):578-578. Published online June 9, 2023
|
|
Hemato-oncology / Original Article
Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma
[corrected-article]
Hee Jeong Cho, Jae-Cheol Jo, Yoo Jin Lee, Myung Won Lee, Do Young Kim, Ho Jin Shin, Sung Nam Im, Ji Hyun Lee, Sung Hwa Bae, Young Rok Do, Won Sik Lee, Min Kyung Kim, Jina Jung, Jung Min Lee, Ju-Hyung Kim, Dong Won Baek, Sang-Kyun Sohn, Joon Ho Moon
Korean J Intern Med. 2023;38(2):238-247. Published online January 26, 2023
Background/Aims: Daratumumab has shown an encouraging antitumor effect in patients with multiple myeloma (MM), and was known to alter the immune properties by off-targeting immunosuppressive cells. Here, we aimed to evaluate the change in absolute lymphocyte count (ALC) as a surrogate marker for pre..
|
|
|